Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen
Breast Cancer is the most common cancer found in women, regardless
of race or ethnicity. According to the American Cancer Society, an
estimated 281,550 new cases of invasive breast cancer are to be
diagnosed in women in the United States during 2021. The incidence
in women in the United States is 1 in 8 (about 12 percent). About
46,600 women are expected to die from breast cancer this year,
though death rates have been steadily decreasing over the past 20
years due to new and ever improving treatment options. HER2-positive
breast cancer is a breast cancer that tests positive for a protein
called human epidermal growth factor receptor 2 (HER2). This protein
promotes the growth of cancer cells. In about 1 of every 5 breast
cancers, the cancer cells have extra copies of the gene that makes
the HER2 protein. HER2-positive breast cancers tend to be more
aggressive than other types of breast cancer. Additionally, in the
later stages of HER2+ disease, when distant metastases are present,
cure becomes less likely and few patients are rendered free of
disease. Therapy in the HER2+ metastatic setting then focuses on
prolonging life and managing disease-and treatment-related adverse
events. Treatment selection must be individualized based upon
patient- and tumor-specific factors, as well as safety and efficacy
profile of available agents, with an emphasis on the combined goals
of tumor control, prolonged survival, and maintenance of patient
quality of life.
Fortunately for patients with HER2-positive advanced breast cancer,
several new agents have been recently approved. They have shown the
ability to improve safety and efficacy outcomes in the approximately
40% of patients living with HER2-positive advanced breast cancer.
With the advancement and complexity of different treatment options,
clinicians are being challenged to quickly diagnose breast cancer
and its corresponding stage, and provide the best evidenced-based
treatment that is available for patients. Between 15% and 20% of
breast cancers cases worldwide are HER2-positive subtypes and
therefore are eligible for HER2-targeting therapies. Therapy for
advanced breast cancer is increasingly personalized, thanks to an
array of molecularly targeted/endocrine therapies indicated for
recurrent/advanced disease. Fortunately for these patients, new
options have recently been approved that have shown the ability to
greatly improve outcomes in patients with HER2-positive advanced
Upon completion of this
activity, participants will be able to:
Examine the clinical and economic
burden of HER2-positive advanced breast cancer in terms of
relative survival, mortality, drug utilization, adverse event
management, and hospitalizations
Describe the molecular heterogeneity
of breast cancer and review how novel treatment approaches are
overcoming obstacles in the management of HER2+ disease
Compare and contrast the efficacy,
safety and mechanisms of action of new and emerging therapies,
including tyrosine kinase inhibitors and antibody-drug
conjugates, for the treatment of HER2-positive advanced breast
Evaluate the evolving role of
emerging therapies in the management of HER2-positive advanced
breast cancer who have failed two or more lines of therapy and
have brain metastases
Explore strategies for anticipating,
recognizing, and managing adverse events of new and emerging
therapies in HER2-positive advanced breast cancer
Apply methods to enable optimal cost
management of new and emerging therapies, including
antibody-drug conjugates and tyrosine kinase inhibitors, to be
realized by multiple HER2-positive advanced breast cancer
stakeholders including managed care organizations
||Mark D. Pegram, MD
Director, Breast Cancer Oncology Program
Suzy Yuan-Huey Hung Endowed Professor of Medical
Stanford University School of Medicine
Stanford Cancer Institute
serves on as a consultant for AstraZeneca, Daiichi
Sankyo, Genentech, Macrogenics, and Seattle Genetics.
His presentation has been peer reviewed for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca, Daiichi Sankyo, and Seagen
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue